AU Patent
AU2013341186A1 — Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Assigned to Bristol Myers Squibb Co · Expires 2015-07-02 · 11y expired
What this patent protects
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R
USPTO Abstract
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R
Drugs covered by this patent
- Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.